MX2017017037A - Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodo fenilamino) fenil][3-hidroxi-3-(piperidin-2-il]azetidin-1-il]-meta nona. - Google Patents
Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodo fenilamino) fenil][3-hidroxi-3-(piperidin-2-il]azetidin-1-il]-meta nona.Info
- Publication number
- MX2017017037A MX2017017037A MX2017017037A MX2017017037A MX2017017037A MX 2017017037 A MX2017017037 A MX 2017017037A MX 2017017037 A MX2017017037 A MX 2017017037A MX 2017017037 A MX2017017037 A MX 2017017037A MX 2017017037 A MX2017017037 A MX 2017017037A
- Authority
- MX
- Mexico
- Prior art keywords
- azetidin
- difluoro
- fluoro
- phenyl
- piperidin
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title abstract 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 229910052740 iodine Inorganic materials 0.000 title 1
- 239000011630 iodine Substances 0.000 title 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se refiere a la sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4- yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1- il]-metanona. La descripción también se refiere a composiciones farmacéuticas que comprenden la sal de fumarato cristalina de (S) - [3,4-difluoro-2- (2-fluoro-4- yodofenilamino)fenil][3-hidroxi-3- (piperidin-2-il)azetidin-1- il]-metanona. La descripción también se refiere a métodos para tratar cánceres que comprenden administrarle a un paciente que lo necesita la sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil ][3- hidroxi-3-(piperidin-2-il)azetidin-l-il]-metanona.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187009P | 2015-06-30 | 2015-06-30 | |
| PCT/US2016/040444 WO2017004393A1 (en) | 2015-06-30 | 2016-06-30 | Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017017037A true MX2017017037A (es) | 2018-04-30 |
| MX390250B MX390250B (es) | 2025-03-20 |
Family
ID=56411938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017017037A MX390250B (es) | 2015-06-30 | 2016-06-30 | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino) fenil][3-hidroxi-3-(piperidin-2-il]azetidin-1-il]-metanona. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10590102B2 (es) |
| EP (1) | EP3317264B1 (es) |
| JP (3) | JP7338950B2 (es) |
| KR (1) | KR102695324B1 (es) |
| CN (2) | CN118290395A (es) |
| AR (1) | AR105483A1 (es) |
| AU (2) | AU2016288209B2 (es) |
| CA (1) | CA2990222C (es) |
| CL (1) | CL2017003475A1 (es) |
| CO (1) | CO2018000086A2 (es) |
| CR (1) | CR20180056A (es) |
| DK (1) | DK3317264T3 (es) |
| FI (1) | FI3317264T3 (es) |
| HK (1) | HK1252433A1 (es) |
| HR (1) | HRP20251507T1 (es) |
| IL (2) | IL256423B (es) |
| LT (1) | LT3317264T (es) |
| MA (1) | MA42301B1 (es) |
| MX (1) | MX390250B (es) |
| MY (1) | MY192545A (es) |
| PE (1) | PE20180692A1 (es) |
| PH (1) | PH12017502414A1 (es) |
| PT (1) | PT3317264T (es) |
| RS (1) | RS67509B1 (es) |
| RU (2) | RU2021132394A (es) |
| SG (1) | SG10202105196YA (es) |
| SM (1) | SMT202500458T1 (es) |
| TW (2) | TWI710556B (es) |
| UA (1) | UA124728C2 (es) |
| WO (1) | WO2017004393A1 (es) |
| ZA (1) | ZA201708760B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ706723A (en) | 2012-10-12 | 2018-07-27 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| EP4272735B1 (en) * | 2015-06-30 | 2025-06-18 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| GB201717809D0 (en) * | 2017-10-30 | 2017-12-13 | Azad Pharmaceutical Ingredients Ag | Process for the production of cobimetinib |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| WO2024111001A1 (en) * | 2022-11-25 | 2024-05-30 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA94571C2 (en) | 2004-10-20 | 2011-05-25 | Мерк Сероно С.А. | 3-arylamino pyridine derivatives |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| CN105106199A (zh) | 2006-12-14 | 2015-12-02 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| NZ706723A (en) | 2012-10-12 | 2018-07-27 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
| JP6835472B2 (ja) | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌の処置のための組成物 |
| CN105246508A (zh) | 2013-03-14 | 2016-01-13 | 基因泰克公司 | Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2016
- 2016-06-24 AR ARP160101900A patent/AR105483A1/es unknown
- 2016-06-30 MY MYPI2017001962A patent/MY192545A/en unknown
- 2016-06-30 CN CN202410400619.5A patent/CN118290395A/zh active Pending
- 2016-06-30 MX MX2017017037A patent/MX390250B/es unknown
- 2016-06-30 CN CN201680039354.4A patent/CN107810183A/zh active Pending
- 2016-06-30 PE PE2017002869A patent/PE20180692A1/es unknown
- 2016-06-30 KR KR1020187000067A patent/KR102695324B1/ko active Active
- 2016-06-30 CR CR20180056A patent/CR20180056A/es unknown
- 2016-06-30 MA MA42301A patent/MA42301B1/fr unknown
- 2016-06-30 AU AU2016288209A patent/AU2016288209B2/en active Active
- 2016-06-30 CA CA2990222A patent/CA2990222C/en active Active
- 2016-06-30 TW TW105120825A patent/TWI710556B/zh active
- 2016-06-30 FI FIEP16738971.7T patent/FI3317264T3/fi active
- 2016-06-30 HK HK18111734.8A patent/HK1252433A1/zh unknown
- 2016-06-30 EP EP16738971.7A patent/EP3317264B1/en active Active
- 2016-06-30 WO PCT/US2016/040444 patent/WO2017004393A1/en not_active Ceased
- 2016-06-30 PT PT167389717T patent/PT3317264T/pt unknown
- 2016-06-30 JP JP2017568050A patent/JP7338950B2/ja active Active
- 2016-06-30 IL IL256423A patent/IL256423B/en unknown
- 2016-06-30 DK DK16738971.7T patent/DK3317264T3/da active
- 2016-06-30 SG SG10202105196YA patent/SG10202105196YA/en unknown
- 2016-06-30 LT LTEPPCT/US2016/040444T patent/LT3317264T/lt unknown
- 2016-06-30 UA UAA201800769A patent/UA124728C2/uk unknown
- 2016-06-30 SM SM20250458T patent/SMT202500458T1/it unknown
- 2016-06-30 RU RU2021132394A patent/RU2021132394A/ru unknown
- 2016-06-30 RU RU2018103172A patent/RU2762181C2/ru active
- 2016-06-30 TW TW109136325A patent/TWI775187B/zh active
- 2016-06-30 IL IL295052A patent/IL295052A/en unknown
- 2016-06-30 HR HRP20251507TT patent/HRP20251507T1/hr unknown
- 2016-06-30 RS RS20251247A patent/RS67509B1/sr unknown
-
2017
- 2017-12-21 ZA ZA2017/08760A patent/ZA201708760B/en unknown
- 2017-12-22 PH PH12017502414A patent/PH12017502414A1/en unknown
- 2017-12-22 US US15/852,280 patent/US10590102B2/en active Active
- 2017-12-29 CL CL2017003475A patent/CL2017003475A1/es unknown
-
2018
- 2018-01-05 CO CONC2018/0000086A patent/CO2018000086A2/es unknown
-
2020
- 2020-01-17 US US16/746,161 patent/US11254649B2/en active Active
- 2020-11-05 JP JP2020184868A patent/JP2021035967A/ja not_active Withdrawn
-
2021
- 2021-01-14 AU AU2021200202A patent/AU2021200202B2/en active Active
- 2021-11-08 US US17/521,396 patent/US20220056010A1/en not_active Abandoned
-
2022
- 2022-11-07 JP JP2022178184A patent/JP2023025000A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017017037A (es) | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodo fenilamino) fenil][3-hidroxi-3-(piperidin-2-il]azetidin-1-il]-meta nona. | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| MX2016011898A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| MX2017001620A (es) | Formas cristalinas de inhibidores de glutaminasa. | |
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| NZ748769A (en) | Nitroxyl donors with improved therapeutic index | |
| MA39778A (fr) | Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX2020007152A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| EA201692270A1 (ru) | Производные нафтиридиндиона | |
| MY185971A (en) | Pyranodipyridine compound | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| PH12016502568B1 (en) | Novel heterocyclic compound | |
| EA201991373A1 (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| MX2014014817A (es) | Compuestos para el tratamiento de inflamacion y dolor. | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| EA201791398A1 (ru) | Производные фумагиллола | |
| AR097890A1 (es) | Compuestos de urea | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |